Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (15202)	1/11/2005 1:46:05 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

You may be right, particularly as you are talking Eastern Europe, so enrolling in the trial may have even bigger implications than it would in the US. That doesn't kill the trial, however, it just kills the implication that the because the trial hasn't yet terminated it must be because the drug is working. The anecdote from the largest site (albeit apparently foreign) that the Xyotax patients went five or six rounds while the taxol patients went only two or three (or maybe it was one or two - I forget) is still striking though. Peter